| Dr Gary Classen, DO | |
|
400 Wabash Ave, Radiology Department, Akron, OH 44307-2433 | |
| (330) 384-6450 | |
| Not Available |
| Full Name | Dr Gary Classen |
|---|---|
| Gender | Male |
| Speciality | Radiology - Diagnostic Radiology |
| Location | 400 Wabash Ave, Akron, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245232867 | NPI | - | NPPES |
| 0322127 | Medicaid | OH | |
| P00278914 | Other | OH | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 34002505 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gary Classen, DO Po Box 931286, Cleveland, OH 44193-1494 Ph: (888) 719-9012 | Dr Gary Classen, DO 400 Wabash Ave, Radiology Department, Akron, OH 44307-2433 Ph: (330) 384-6450 |
News Archive
An important focus of medical research today is on translating new scientific discoveries into advances in clinical care that will lead to meaningful improvements in health outcomes. Ongoing ethical, legal, and social issues in this era of "translational" research are the subject of a special symposium in the October issue of The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation.
NanoViricides, Inc. announced today that March 29th, 2012 has been confirmed by the US FDA as the date for its initial meeting with the Company's scientists. This pre-IND meeting will focus on FluCide, designated as NV-INF-1, the Company's novel anti-influenza drug.
Fractional flow reserve (FFR)-guided drug-eluting stenting reduces death, myocardial infarction or urgent revascularisation, as compared to medical therapy in patients with stable coronary artery disease (CAD), according to the results of the FAME 2 trial presented for the first time today at ESC Congress by principal investigator Dr Bernard De Bruyne (Belgium).
Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes.
› Verified 5 days ago
J. Eric Blum, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-4028 Fax: 330-375-6295 | |
William Fitzgerald Demas, M.D., F.A.C.R. Radiology Medicare: Accepting Medicare Assignments Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-3557 Fax: 337-376-1302 | |
Dr. Tom Alex Stamatis, Radiology Medicare: Accepting Medicare Assignments Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-3167 Fax: 330-375-6217 | |
Bassey N. Essiet, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 525 E Market St, Akron Radiology, Inc., Akron, OH 44304 Phone: 330-375-3043 Fax: 330-375-7932 | |
Dr. Anand Bharat Desai, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 161 N Forge St, Ste G90, Akron, OH 44304 Phone: 330-375-3557 Fax: 330-376-1302 | |
Mark Alan Richards, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 2303 W Market St, Suite 110, Akron, OH 44313 Phone: 330-867-7274 Fax: 330-867-2495 | |
Susan M Hong, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 161 N Forge St, Suite G90, Akron, OH 44304 Phone: 330-375-4485 |